Most Recent
Court throws out Merck Sharp & Dohme’s Januvia patent extension
The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an "untenable" patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.
Novartis wins injunction to stop generic version of blockbuster MS drug, for now
Swiss drug giant Novartis has secured an injunction temporarily blocking drug maker Pharmacor from launching a generic version of the company’s top-selling MS drug Gilenya in Australia.
Novartis sues to stop generic version of blockbuster MS drug
Swiss drug giant Novartis has sued generic drug maker Pharmacor to halt its launch of a generic version of the company's top-selling MS drug Gilenya.
Sandoz cross-claim seeks to block Merck Sharp & Dohme’s Januvia patent extension
Generic pharmaceutical company Sandoz has hit back in an intellectual property lawsuit by Merck Sharp & Dohme, filing a cross-claim that seeks to undo an extension of time granted to the US drug manufacturer for a patent relating to its multibillion dollar Januvia and Janumet diabetes drugs.